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Candida albicans is an opportunistic fungal pathogen that normally exists as a harmless commensal in humans. In instances
where host debilitation occurs, Candida can cause a range of clinical infections, and whilst these are primarily superﬁcial,
eﬀecting mucosal membranes, systemic infections can develop in severely immunocompromised individuals. The mechanism
of host immunity during commensal carriage of C. albicans has been intensively studied. In this paper, we present the most
recent information concerning host recognition of C. albicans leading to cytokine production and the subsequent T-cell responses
generated in response to C. albicans. Particular focus is given to the role of the IL-12 cytokine family including IL-12, IL-23, IL-27,
and IL-35, in host immunity to Candida.C D 4 + T-cells are considered crucial in the regulation of immunity and inﬂammation. In
this regard, the role of Th1/2, helper cells, together with the recently identiﬁed Th17 and Treg cells in candidosis will be discussed.
Understanding the detailed mechanisms that underlie host immunity to Candida not only will be of beneﬁt in terms of the
infections caused by this organism but could also be exploited in the development of therapeutic interventions for other diseases.
1.Introduction
Candida albicans is normally a harmless commensal fungus
of humans and has been shown to colonise up to 70% of
individuals without any detriment to health [1, 2]. During
commensal carriage, a balance exists between the body’s
own defence systems and the continued persistence of the
organism at a level that does not induce disease. However, in
instanceswherethereisdisruptiontothisequilibrium,either
through environmental factors that promote the growth of
Candida or through a weakening of the host’s immune sys-
tem, then proliferation of Candida and subsequent infection
can arise. Clear examples of this occur in HIV-infected
individuals or those patients receiving chemotherapy for
treatment of cancer [3–5]. In these situations, a depletion
of host T-cell function and that of other cells involved in
establishing an appropriate immune response occurs with
the result that candidosis can ensue.
Candidosismostfrequentlypresentsassuperﬁciallesions
of moist mucosal membranes, particularly those of the
vagina and oral cavity. However, in severely immuno-
compromised individuals and particularly where there is
neutropenia, systemic infections can develop which are
often fatal. Most immunocompetent individuals have an
underlying acquired immunity which is thought to prevent
dissemination of mucosal candidal colonisation through the
body. Individuals who are existing carriers of Candida are
however deemed to be at an increased risk of developing
systemic forms of the disease. The type of immune response
generated is key in determining whether C. albicans clear-
ance, infection, or commensal carriage occurs.
Oral candidosis is not a single disease entity and four dis-
tinctclinicalformsofprimaryinfectionarerecognised.Pseu-
domembranous candidiasis frequently occurs in newborn
babies and in these instances is associated with an immature
immune system. In older individuals the condition occurs
when there is mild debilitation or local immunosuppression
in the host as seen in asthma suﬀerers who use a corticos-
teroid inhaler as part of their treatment regime [6]. With the
advent and escalation of HIV infection and AIDS, chronic
forms of pseudomembranous candidosis are evident, which
frequently reoccur despite administration of antifungals.
Acute erythematous candidosis is an infection that
presents as a painful reddened lesion on the dorsum of the2 Clinical and Developmental Immunology
tongue and is associated with an overgrowth of Candida
following broad spectrum antibiotics. Such lesions tend
to resolve spontaneously after antibiotic therapy has been
completed [7]. Chronic erythematous candidosis is the most
prevalent form of oral candidosis aﬀecting over 65% of
denture wearers, often asymptomatically. It is thought that
poor denturehygiene contributesto theinfection thatoccurs
onthepalatebeneaththeupperﬁttingsurfaceofthedenture.
Chronic hyperplastic candidosis is another chronic infection
that presents as a white lesion on the oral mucosa, most
frequently bilaterally on the buccal mucosa. The infection
is particularly signiﬁcant as it is associated with malignant
change at the lesional site, although the role of Candida in
this process remains unclear [8].
In addition to these primary infections, secondary oral
infections are recognised and include angular cheilitis and
median rhomboid glossitis. Angular cheilitis presents as
lesions in the angles of the mouth from which Candida
albicans is frequently recovered, often in combination with
the bacterium Staphylococcus aureus [9]. Median rhomboid
glossitis presents as a chronic tongue lesion within which
Candida is detected by biopsy in over 85% of cases.
Chronic mucocutaneous candidiasis (CMC) is a collec-
tive term for a range of syndromes that result in the per-
sistent occurrence of severe and diﬀuse cutaneous candidal
infections. These infections manifest on the skin, nails, and
mucous membranes (including the oral cavity) of CMC
patients. Invariably, there is an underlying dysfunction in
cell-mediatedimmunitythatleadstotheoccurrenceofCMC
[10].
Neutrophils and macrophages are major components of
the innate immune response and play an important role in
the control of mucosal C. albicans colonisation. These cells
are responsible for the phagocytosis of Candida and can
kill the fungus through release of reactive oxygen species
(ROS). Cytokines produced by T-cells, such as IFN-γ and IL-
17 will promote neutrophil and macrophage activity against
Candida [11, 12]. Neutrophils and macrophages recognise
C. albicans via pattern recognition receptors (PRRs) and
following recognition will also produce an array of cytokines
and chemokines.
Dendritic cells (DCs) function as professional antigen
presenting cells (APCs) that detect the presence of Candida
at mucosal sites. DCs will interact with the fungus and
become activated, with phagocytosis being the ﬁrst action
of the activated cell. After phagocytosis, DCs migrate to the
nearest lymph node where the Candida antigen is processed
and presented by the DCs to na¨ ıve CD4+ T-cells [13–18].
The na¨ ıve T-cells then diﬀerentiate into mature eﬀective T-
cells under the direction of the DCs [19]. Examples of such
diﬀerentiated T-cells include T-helper 1 (Th1), T-helper 2
(Th2), T-helper 17 (Th17), and regulatory T-cells (Tregs).
T h el a t t e rs e r v et oc o n t r o lT - c e l lr e s p o n s e st oa v o i da n
overreactive immune response [20], and in this manner, an
inducible Treg cell development can balance pathogenic and
physiologic host immune responses [21–24].
Activated DCs produce a variety of cytokines to direct T-
cell diﬀerentiation, and the IL-12 family of cytokines (IL-12,
IL-23, IL-27, and IL-35) would appear to play an important
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Figure 1: Schematic representation of structure of members of the
IL-12 famil.
role in this T-cell diﬀerentiation [25–27]. It is the relative
level and type of cytokines that are expressed by the DCs
into the local environment that will ultimately determine
type of T-cell response (Th1, Th2, and Th17) generated. In
this paper, we will discuss the role that members of the IL-12
cytokine family play in the host immune responses and their
possible relationship in eﬀecting either tolerance of fungal
colonisation or the development of oral infection.
2.Candida albicans Recognition by Host DCs
As previously mentioned, the main function of DCs is to act
as professional APCs that link the innate and adaptive host
immune responses in combating host invading pathogens.
Humanperipheralblood-derivedDCsarethemainsourceof
mucosal DCs, and it is these immature cells that will initially
recognise Candida through various surface protein antigens
and mannose and β-glucans in the fungal cell wall [5].
The initial antigen recognition by DCs is mediated
through the expression of pattern-recognition receptors
(PRRs) on the surface of DCs. The nature of this interaction
between DCs and the fungus is the key factor in determining
whether immune activation or tolerance occurs [8]. The
ﬁrst group of PRRs identiﬁed were the toll-like receptors
(TLRs) and to date, 10 of these TLRs have been identiﬁed
in humans, with TLR2, TLR4 TLR6, and TLR9 implicated
in host cell recognition of C. albicans [28–30]. TLRs are
type I membrane proteins and are either homodimer or het-
erodimer receptors, recognising various pathogen antigens
including proteins, cell wall sugars, or DNA/RNA molecules
(collectively referred to as pathogen-associated molecular
patterns or PAMPs). Recently a new group of type II cell
membrane molecules have been linked to the recognition of
fungi by host cells, and these are referred to as C-type lectin-
like receptors (CTLLRs) [31]. Dectin-1 and 2 are examples
of CTLLRs and interact, respectively, with the β-glucan
and mannose components exposed in the C. albicans cell
wall [32, 33]. Binding of dectin-1 to β-glucan components
of C. albicans will trigger host immune cell responses,
and signalling is thought to be mediated through the Syk
kinase pathway and the transmembrane adaptor caspase
recruitment domain 9 (CARD9) leading to induction of the
cytokines IL-23 and IL-6, but not IL-12 [34]. Interestingly
in CMC patients, a CARD9 point mutation that leads to the
generation of a premature termination codon (Q295X) has
recently been identiﬁed [35].Clinical and Developmental Immunology 3
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Figure 2: Heat-killed Candida albicans (HKC) stimulated THP-1 cell for Ebi3 and TLR2/4 expression. (a) THP-1 cells were stimulated with
1 × 105 HKC /mL and 100ng/mL LPS for indicated time. The Ebi3 mRNA was detected by RT-PCR. The RNA equal loading was shown by
β-Actin RT-PCR. (b) THP-1 cells were stimulated with two clinical strains of C. albicans (S1 and S2) for overnight. The Ebi3 expression was
presented by band density ratios of Ebi3 over β-Actin. (c) IL-27 cytokineS were measured by a human IL-27 ELISA (R&D system) in a cell
culture with pretreated THP-1 cell with indicated increase density of heat killed Candida followed by low dose LPS stimulation. (d) TLR2
and 4 mRNA expression was increased by 1 ×106 HKC /mL.4 Clinical and Developmental Immunology
Synergistic eﬀects of dectin-1 with TLR2 and TLR4
signalling have been shown to enhance proinﬂammatory
cytokine production by human peripheral blood monocytes
(PBMCs) [36]. Recently, mutation in the human dectin-1
gene was identiﬁed in 4 women within a single family, who
were all suﬀering from vulvovaginal candidosis. Monocytes
isolatedfromthesehomozygotemutantpatientsallexhibited
signiﬁcantly reduced binding to C. albicans. These cells also
produced less IL-6 and IL-17 cytokines [37].
3. The Role of the IL-12 CytokineFamilyin
Host Immunity
Many cytokines can be produced by APCs, although it is
those belonging to the IL-12 family that would appear to be
signiﬁcant in controlling T-cell diﬀerentiation. This family
of cytokines consists of at least 4 heterodimeric protein
members and includes the cytokines IL-12, IL-23, IL-27 and
IL-35 (Figure 1).
The IL-12 cytokine is composed of two protein subunits
called p35 and p40 and was the ﬁrst cytokine shown to be
able to drive the diﬀerentiation of na¨ ıve T-cells into Th1
cells [38, 39]. The IL-23 cytokine also shares the same p40
subunit as IL-12, but in IL-23 this is combined with a p19
subunit. IL-23 was discovered almost 10 years after IL-12
[40] and has also been implicated in the later stages of
Th1 cell diﬀerentiation. Followup studies have subsequently
shown that IL-23 is in fact, functionally distinct from IL-
12, as it not only acts on Th1 cells, but also stimulates
Th17 cells to produce IL-17 [30, 41]. Interestingly, IL-23
also acts on macrophages to drive osteoclast development in
inﬂammation-mediated bone pathology [42].
The IL-27 cytokine comprises of a p40-related protein
referred to as EBi3 (Epstein-Barr virus induced gene 3)
together with a subunit known as p28, (a p35-related pro-
tein). The EBi3 gene was ﬁrst identiﬁed in 1996, following its
expression during B-lymphocytes infection with the Epstein
Barr Virus. The gene product is a secreted glycoprotein
related to p40 [43]. Later, during research investigating
IL-6 homologous proteins, its partner subunit, p28 was
discovered. The p28, protein was only found to be eﬃciently
secreted when coupled with EBI3. Following this discovery,
the heterodimeric protein of EBi3 and p28 was named IL-27
[44].
Initially, the function of IL-27 was again thought to be
similar to IL-12 in driving early stage Th1 cell development.
Further study has however shown that IL-27 is also able
to induce IL-10 production from Treg cells which can
inhibit Th17 responses [45, 46]. In this regard, IL-27
can suppress inﬂammation in inﬂammatory mouse disease
modelsincludingthecollageninducedarthritis(CIA)mouse
model [46, 47].
In addition to associating with p28 in IL-27, the EBi3
subunit can also couple with p35 to facilitate secretion of
the latter [48]. The function of the EBi3/p35 heterodimer
was not known until relatively recently when studies using
a recombinant EBi3/p35 protein in a rheumatoid arthritis
mouse model [46] showed that joint inﬂammation was
eﬀectively resolved by the recombinant protein. It was sug-
gested that the therapeutic mechanism of this recombinant
protein was through induction of Treg cell development and
IL-10expressionwiththesubsequentsuppressionofTh1and
Th17 responses [46]. Furthermore, in the absence of EBi3 or
p35 subunit production, Treg cells are unable to resolve gut
inﬂammation in mouse inﬂammatory bowel disease (IBD)
[49]. EBi3 and p35 are both highly expressed by mouse
Treg cells, thus seemingly providing a key component of the
immune regulating function of these cells. In cases where
Treg cells are deﬁcient in either the EBi3 or p35 genes, a
reduced ability to suppress eﬀector T-cell proliferation is
evident [49].
The EBi3/p35 heterodimeric protein has since been
named IL-35 [49], and whilst the functional eﬀect of IL-
35 in mouse models has clearly been seen, the role of this
particular cytokine in immune regulation of humans still
remains unclear.
3.1. The Role of IL-12 in Candidosis. Ac r i t i c a lr o l eo fI L - 1 2
in the immune response during human fungal infection has
beenreported.Theβ1subunitoftheIL-12receptorisutilised
by both IL-12 and IL-23 for cell signalling transduction and
is encoded by the IL12RB1 gene. Recently, two unrelated
Mexican patients were found to share a common mutation
in the IL12RB1, gene and both were found to suﬀer from
uncontrolled Bacille Calmette-Gu´ erin (BCG) and C. albicans
infection resulting in their early deaths by the ages of 4 and
16 years [50].
DC maturation is essential in the generation of an
immune response following C. albicans stimulation. Human
PBMC populations contain a large number of immature
DCs and when stimulated with C. albicans, IL-12p40 mRNA
expression is not detected [51]. However, in vitro derived
and matured DCs from PBMC do respond to C. albicans
stimulationwithsubsequentIL-12production,whichinturn
stimulates Th1 cell diﬀerentiation [52].
The importance of IL-12p40 in controlling fungal infec-
tion has been shown in C. albicans infected mouse mod-
els. Mannoprotein from the fungal pathogen Cryptococcus
neoformans appears to protect mice from subsequent intra-
venous challenge with C. albicans. However neutralisation of
the IL-12 cytokine using a rat anti-IL-12 antibody removes
this protective eﬀect, indicating an involvement of IL-12 in
the process [53]. An IL-12 recombinant protein fused with
C. albicans antigen (enolase) has also been reported as being
able to protect mice during C. albicans infection [54].
Both mucosal and systemic models of mouse candidosis
have been developed [55–57]. Based on these, it has been
shown that IL-12p40 deﬁcient mice exhibit signiﬁcantly
higher levels of C. albicans colonisation than their wild-type
littermates. However, systemic infection with intravenously
inoculation of Ca l b i c a n sappears unaﬀected by IL-12p40
deﬁciency [58].
3.2. The Role of IL-23 in Candidosis. Conceivably, the results
obtained with the IL-12p40 gene knockout mice described
above may also be the result of deﬁciencies in IL-23Clinical and Developmental Immunology 5
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Figure 3: Peripheral blood monocytes from a healthy individual responded to C. albicans stimulation for Th1 cytokine (IFNγ) production,
Th17 cytokine (IL-17) production, but not Th2 cytokine (IL-4) production. The cytokines were measured with CBA kit (BD bioscience).
production, since IL-12 and IL-23 share a protein subunit
(IL-12p40). Recently, studies have shown that IL-23 may
indeed play a key role in controlling vaginal candidosis, with
the IL-23 cytokine, together with IL-6 readily detected in
vaginal secretions of infected women [12, 59]. Even though
DCs isolated from patients with candidosis demonstrate
reduced maturation, they do have the ability to produce IL-
23 and IL-6 [19], which seemingly can play a direct role in
the maintenance of Th17 responses [60–62].
Candida infection in both immune competent and
immunosuppressed mice generally leads to enhanced IL-
23p19 expression. Immune competent mice produce a much
higher and more prolonged expression of IL-23p19 mRNA
at mucosal tissue sites compared with those mice that
are immunosuppressed [12]. Mice that are Th17 and IL-
17 receptor deﬁcient develop an inappropriate immune
response[63],andotherresultsindicatethatoverproduction
of IL-23 and IL-17 can impair the host immune system
in its ability to combat C. albicans infection, despite mice
exhibiting inﬂammation [41].
3.3. Involvement of IL-27 and IL-35 in Candidosis. IL-27 and
IL-35 are cytokines that regulate the production of IL-17 and
IL-10 from Th17 and Treg cells, respectively. IL-27 and IL-35
both suppress IL-17 production by Th17 cells and promote6 Clinical and Developmental Immunology
IL-10 production by Treg or T suppressor cells [45, 46].
Although IL-27 can enhance APC and DC maturation by
stimulation of MHC I and II expression in human THP-1
monocytic cells [64], an autocrine-mediated regulation has,
as yet, not been demonstrated.
IL-12p35 knockout mice tend to have lower fungal
burden and show no overt disease during oral C. albicans
infection [63]. Since IL-12p35 is a component of IL-35, the
result of this study demonstrated that the immunosuppres-
sive eﬀect of IL-35 can be countered by gene disruption,
resulting in enhanced immunity against fungi infection.
To date, there has been limited laboratory research into
the role that IL-27 and IL-35 may have in the immune
response to candidosis. Recent experiments performed in
our laboratory (unpublished data) have shown that when
THP-1 cells are challenged with heat killed C. albicans, an
enhancedexpressionofEBi3(asubunitofbothIL-27andIL-
35) occurs compared with exposure to bacterial lipopolysac-
charide alone (Figure 2(a)). Furthermore we have found that
clinical strains of C. albicans exhibit strain variation in their
ability to induce EBi3 mRNA expression in the THP-1 cells
(Figure 2(b)). Prechallenging of THP-1 cell with heat killed
C. albicans also leads to a detectable level of IL-27 expression
after initial low dose LPS stimulation (Figure 2(c)), which
can be explained by enhanced expression of TLR2 and TLR4
(Figure 2(d)).
4.T-cellImmunityinControlling
Fungal Infection
As previously mentioned, the binding of PRRs to PAMPs on
the Candida cell surface activates DCs and other professional
APCs. Activated APCs can phagocytose C. albicans and
present its antigens with MHC II to T-cell receptors (TCRs)
of na¨ ıve CD4+ T-cells. The interaction of the DC and
T-cell usually occurs within lymphoid tissue immediately
after migration of the APC from the site of infection. APC
binding with na¨ ıve CD4+ T-cells will result in the directed
diﬀerentiation and proliferation of various T-cell subsets.
The type of subset of T-helper cells that is developed is
dependentonthecytokineenvironmentsuppliedbytheAPC
which will have a major bearing on the ensuing immune
response.
Three signals are provided by the APC to the na¨ ıve CD4+
T-cell. The ﬁrst is through interaction of the presented anti-
gen and the TCR. The second is provided by costimulatory
molecules on the APCs which bind to costimulatory recep-
tors on T-cells. The third signal involves the production of
cytokines by the APCs, which activate appropriate receptors
on T-cell surfaces and induce T-cell diﬀerentiation [65–68].
Many cytokines can be produced by activated APCs, and
these can either be pro- or anti-inﬂammatory [33, 34, 69].
Results from animal models clearly show that T-cells are
pivotal in the control of Candida colonisation of the host
[70–72].
Protective adaptive immune responses to Candida were
initially thought to be mediated by CD4+ Th1 cells [15, 72],
with Th2 cells associated with a failure to protect resulting
in Candida infection [4, 73]. More recently, Th17-mediated
immunity has been highlighted as a protective mechanism
against Candida infection [74, 75].
4.1. Th1 and Th2 Cell Responses in Candidosis. By deﬁnition,
a Th1 cell is a CD4+ T-cell that has the ability to respond
to a speciﬁc antigen and produce the cytokines IFNγ,I L - 2 ,
and TNFα. Similarly, Th2 cells are CD4+T-cells that produce
the cytokines IL-4, IL-5, IL-13, and IL-25 in response to
antigen stimulation. It has been demonstrated that Th1 cells
play an important role in the defence of mice against C.
albicans infection [76, 77]. Studies that have neutralised
IL-4 (a Th2 cytokine) production in mice resulted in an
induced Th1 response with an associated resistance to C.
albicans infection [78]. In addition, IFNγ receptor-deﬁcient
mice exhibit a greater susceptibility to C. albicans systemic
infection. In cases where human peripheral blood derived
DCs are stimulated with Ca l b i c a n sand cocultured with
autologous CD4+ T-cells, a Th1 response is also elicited
[52]. Defects in these Th1 cell responses lead to a signiﬁcant
impairment in host defences against Candida [79].
Although a protective role of Th1 responses has convinc-
ingly been showed in both humans and mice, contrasting
results concerning Th1 or Th2 cytokine production at
mucosal infection sites have been reported [71], and in some
patients with candidosis, these cytokines may not even be
detectable [80]. These ﬁndings may however be a result of
diﬀerent assay sensitivities in respective laboratories.
4.2. Th17 in Candidosis. Th17 cells produce the cytokines
IL-17A, IL-17F, IL-21, and IL-22 [81]. Evidence for the
importance of Th17 cells in protecting against Candida
infection has been through experiments involving mice
deﬁcient in production of Th17 cells, the expression of IL-
17, or for the receptor for IL-17. In such studies, the deﬁcient
mice exhibit greater susceptibility to oral infection with C.
albicans [63]. Furthermore, human PBMCs from patients
with chronic mucosal candidosis have been shown to exhibit
reduced Th17 cell responses compared with PBMCs from
healthy individuals after challenge with C. albicans [82, 83].
Mouse dectin-1 activated DCs direct Th17 cell develop-
ment in vitro, and in a mouse candidosis model, CARD9-
dependent Th17 development has been demonstrated [34].
IL-22 in mice plays a protective role against C. albicans
infectionwhenTh1responsesareimpaired[84].Inaddition,
C. albicans-speciﬁc Th17 cells are readily detected in healthy
individuals with a C. albicans mediated induction of Th17
responses observed via DCs [12]. Human monocyte derived
DCs stimulated with the generally nonpathogenic Saccha-
romyces cerevisiae yeast induce cell-mediated Th1 responses,
while C. albicans yeast or hyphae pulsed DCs shifted T-cell
responses towards Th17 [85].
Hyphae of C. albicans have been shown to stimulate
human monocyte-derived DCs to produce IL-23 and not IL-
12. This is in contrast with C. albicans yeast which stimulate
IL-12 production, with IL-23 only generated in response
to high yeast concentrations. Such ﬁndings would suggest
that it is the hyphal form of C. albicans that is responsibleClinical and Developmental Immunology 7
for triggering Th17 responses in vivo. Interestingly, human
memory cells speciﬁc for C. albicans are derived from Th17
subsets that express the chemokine receptors CCR6 and
CCR4 for skin and mucosal homing [86]. The exact function
of this chemokine receptor expression in the control of
in vivo Th17 cell migration does however remain unclear.
Moreover, PBMCs from a CMC patient were found to
produce lower levels of IL-17A and IL-22 in response to
C. albicans stimulation compared with cells from a healthy
individual.AdecreasednumberofCCR6+ CD4+ T-cells have
also been found in CMC patients [87].
4.3. Regulatory T-cells in Candidosis. Regulatory T-cells
(Treg) are CD4+CD25high T-cells which can suppress CD4+T
eﬀective cells, including the proliferation and diﬀerentiation
of Th1 and Th17 cells. Such a suppression leads to reduced
inﬂammatory responses against Candida in mucosal and
disseminated infections [19, 28].
Candida albicans might be able to induce immune tol-
erance through interaction with DCs via Toll/IL-1 receptor
domain-containing adaptor inducing IFN-β (TRIF) and
STAT3-dependent signal transduction that activates Treg
diﬀerentiation. Treg cells express TLR2 and proliferate under
stimulation with TLR2 ligands and TCR activation. More-
over TLR2−/− mice are more resistant to C. albicans infection
and demonstrate signiﬁcantly reduced IL-10 production.
This would suggest that Treg cell function may be regulated
directly by C. albicans to avoid unnecessary inﬂammatory
responses [28, 29]. The balance between Th17 and Treg cells
in mucosal tissue has been suggested as the determining
factor for either commensal carriage or infection with C.
albicans [13, 88]. However, human and animal models have
yet to show any direct evidence that an over production of
Treg cells and enhanced Treg function leads to C. albicans
infection.Indirectly,Treginvolvementincandidosishasbeen
demonstrated using TNFα receptor-related gene (GITR)
knockout mice. The wild-type mouse is associated with
high expression of CD4+CD25+ T-cells (Treg). The GITR
knockout mice have enhanced resistance to systemic C.
albicans infection with an accompanying highly developed
Th1 cell phenotype. Furthermore DCs produce elevated IL-
12 levels when added to cultures of CD4+CD25+ T-cells
from GITR knockout mice, when compared with wild-
type mice [89]. This ﬁnding indicates that Treg cells may
serve to suppress the protective Th1 role in candidosis. As
previously mentioned, the cytokine IL-35 consists of the
subunits EBi3 and IL-12p35 and would appear to promote
Treg diﬀerentiation [46] and therefore control Treg immune
suppression [49]. Mice deﬁcient in the IL-12p35 gene are
highly resistant to oropharyngeal candidosis [63], which
again provides indirect evidence for the role of Treg in
suppressing T-cell defensive responses against C. albicans
infection.
T-cell responses can be generated by coculture of a
pathogen’s antigen with peripheral blood monocytes. After
several days of culture, the antigen-speciﬁc T-cells can be
recalled to produce cytokines, such as the Th1 cell cytokine
IFNγ [90]. We have isolated human PBMC from a healthy
donor and recalled the T-cell response using heat killed C.
albicans. Predominant Th1 and Th17 responses based on the
cytokine proﬁles were seen at days 1, 3, and 7 after culturing
PBMC with heat killed C. albicans (Figure 3).
5. Summary
DCs are the key immune surveillance cells at mucosal
sites and mediate their surveillance through cell surface
expression of pattern recognition receptors (PRRs). The
colonisation of mucosal surfaces by C. albicans can be
detected through interaction of PRRs and surface antigens
on Candida, which will ultimately lead to cell signalling
and phagocytosis. Activated DCs migrate to local lymph
nodeswheretheprocessedCandidaantigensarepresentedto
na¨ ıve CD4+ T-cells. T-helper and Treg cells will diﬀerentiate
under the direction of cytokines produced by the DCs. The
IL-12 cytokine family are largely involved in driving this
T-helper cell development which in turn is essential for
subsequentmacrophageandneutrophilkillingofC.albicans.
Both Th1 and Th17 responses are considered protective,
whilst Th2 and Treg responses may have a suppressive eﬀect
on host immunity against candidosis. The cytokine IL-12
drives Th1 development, whilst IL-23 is involved in directing
and maintaining Th17 function. IL-27 has two eﬀects in
terms of regulating CD4+T-cell responses. On one hand,
IL-27 assists IL-12 in the early stage development of Th1
cells; however, like IL-35, IL-27 also serves to suppress Th17
activity. The role of IL-12 cytokines in immune function
against Candida is still not completely understood, and our
current knowledge particularly for the novel IL-12 family
members, IL-27 and IL-35, needs to be enhanced. Additional
research is warranted in order to understand the molecular
mechanism of host against C. albicans infection, which will
not only beneﬁt in the treatment of candidosis but could
also oﬀer therapeutic options in the treatment of other
inﬂammatory conditions.
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